Prelude Therapeutics Inc (NASDAQ: PRLD) — Perfil da empresa, notícias e dados financeiros
Prelude Therapeutics focuses on innovative oncology treatments, developing small-molecule therapeutics targeting cancer pathways.
Prelude Therapeutics Inc
Prelude Therapeutics (NASDAQ:PRLD) is a biotechnology company dedicated to advancing innovative treatments in oncology and rare diseases. With a keen focus on drug discovery and development, Prelude is working diligently to bring novel cancer therapies from the laboratory to clinical trials, aiming to address unmet medical needs. Their pipeline includes a range of small-molecule therapeutics designed to target key signaling pathways in cancer cells, showcasing their commitment to transforming the landscape of cancer treatment. Central to the company's objectives is the pursuit of scientific breakthroughs that can lead to life-changing treatments for patients battling cancer and other serious diseases.
Resumo
Operações
Produtos e/ou serviços de Prelude Therapeutics Inc
- PRT543, a small molecule inhibitor targeting PRMT5, designed for treating a variety of cancers including solid tumors and hematological malignancies.
- PRT811, a PRMT5 inhibitor with potential broad application in solid tumors, particularly glioblastoma.
- PRT2527, a CDK9 inhibitor aiming at treating MYC-driven cancers, including hematologic malignancies and solid tumors.
- PRT1419, an MCL1 inhibitor intended for patients with hematologic malignancies, addressing a key survival protein in cancer cells.
- PRT3645, a potent inhibitor focusing on PI3K delta, developed for treating hematologic malignancies.
equipe executiva do Prelude Therapeutics Inc
- Krishna VaddiFounder, CEO & Director
- Bryant David LimCFO, Chief Legal Officer & Corporate Secretary
- Peggy A. ScherleChief Scientific Officer
- Aimee CrombieSenior VP and Head of Strategic Planning & Operations
- Madhu PudipeddiSenior Vice President of Technical Operations
- Robert A. Doody Jr.Senior Vice President of Investor Relations
- Michele PorrecaChief People Officer
- Andrew P. CombsExecutive VP & Chief Chemistry Officer
- Naveen BabbarSenior Vice President of Translation Medicine
- Wan-Jen HongSenior Vice President of Clinical Development
Principais indicadores financeiros
Resultados divulgados pela Prelude Therapeutics Inc, em USD.
- Cap. de mercado
- 309,6 mi
- Receita (TTM)
- 22,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- -269.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 12,1 mi | -104,6 mi | -99,5 mi | |
| 7 mi | -139,7 mi | -127,2 mi | |
| 0 | -132,3 mi | -121,8 mi | |
| 0 | -123,5 mi | -107,3 mi |